Evidence map›Paper›PMID 32816099›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021

A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model.

Finny Monickaraj, Sreenivasa R Oruganti, Paul McGuire, Arup Das

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Finny MonickarajDepartment of Surgery, University of New Mexico School of Medicine, MSC10 5610, Albuquerque, NM, 87131, USA.
Sreenivasa R OrugantiDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Paul McGuireDepartment of Cell Biology & Physiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Arup DasDepartment of Surgery, University of New Mexico School of Medicine, MSC10 5610, Albuquerque, NM, 87131, USA. adas@unm.edu.
New Mexico VA Health Care System · USUniversity of New Mexico · US

Funding

Inflammatory Chemokines: A Novel Target in Early Diabetic RetinopathyR01EY022327 · NEI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI DAS, ARUP · 2013 to 2015
$1.1M
Sphingosine 1-Phosphate: A New Target for Early Diabetic RetinopathyI01BX001801 · VA · ALBUQUERQUE VA MEDICAL CENTER · PI DAS, ARUP · 2013 to 2015
–
Biomedical Laboratory Research and Development, VA Office of Research and Development IO 1BX001801BLRD VA I01 BX001801NEI NIH HHS EY022327NEI NIH HHS R01 EY022327
6 · The paper itself

Abstract

purposeWe have previously shown that the chemokine CCL2 plays an important role in monocyte trafficking into the retina and alteration of the BRB in an animal model of diabetic retinopathy. In this study, we examined the effect of pharmacologically targeting the chemokine pathway to reduce the increased retinal vascular permeability in this model.

methodsC57BL/6 J mice were made diabetic using streptozotocin. After 4 months of diabetes, mice (n = 10) were treated by intraperitoneal injections of TAK-779 (dual CCR2/CCR5 inhibitor) (30 mg/kg) daily for 2 weeks. Retinal vascular permeability and protein expression were done using western blot. The SDF-1 levels were measured by ELISA. Immune cell infiltration in the retinas was measured using flow cytometry.

resultsThe dual inhibitor significantly decreased retinal vascular permeability in diabetic animals. There was a significant reduction in macrophage/microglia infiltration in the retinas of treated animals. Levels of SDF-1 and ICAM-1 were significantly reduced and the tight junction protein ZO-1 level was increased, and phospho-VE-Cad was significantly reduced with drug treatment.

conclusionsA chemokine receptor inhibitor (CCR2/CCR5) can reduce retinal vascular permeability in diabetic animals. Targeting the chemokine pathway pharmacologically may be used as a novel therapeutic strategy in management of diabetic macular edema.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic RetinopathyMacular EdemaAnimalsBlood-Retinal BarrierCapillary PermeabilityMiceMice, Inbred C57BLReceptors, CCR2Receptors, ChemokineRetinaRetinal VesselsCcr2 protein, mouseReceptors, CCR2Receptors, ChemokineCCR2CCR5ChemokineDiabetic macular edemaRetinal vesselsTight junction proteinVascular permeability

Identifiers

PMID32816099
PMCPMC7796894
OpenAlexW3081473441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.